RadMD First to Offer CME-Certified Education and Training For Medical Imaging in Clinical Trials
DOYLESTOWN, Pa., July 28, 2009-RadMD, Inc. has become the first company to offer a broad range of accredited CME courses in the area of medical imaging for pharmaceutical, medical device and biotech clinical trials.
The comprehensive education and training is offered through the company's Blinded Reader and Investigator Training Institute (BRITI). RadMD is partnering with International Center for Postgraduate Medical Education (ICPME) to obtain the CME certification.
"A huge number of clinical trials use medical imaging to demonstrate effectiveness," said Lisa Schleelein, MEd, ICPME's director of CME. "The primary goal of CME activities is to improve practice performance and patient care. RadMD is contributing to the overall quality of this process with educational activities that improve the utilization, acquisition and interpretation of medical images."
Founded by medical imaging experts Kohkan Shamsi, MD, PhD, and Richard Patt, MD, RadMD will offer both CME-certified and non-CME course modules providing clinical trial personnel with formalized training and testing on a variety of topics related to the use of medical imaging in clinical trials. The curricula were developed to reduce bias, increase data reliability and improve the accuracy of the results.
"The FDA emphasizes the role of training trial personnel but there are no standards in place to govern the use of medical imaging for this purpose," said Dr. Richard Patt, co-founder of RadMD. "Other companies in our industry use education as a marketing tool to sell their services; we recognize the crucial importance of independent, peer-reviewed validation for education and training."
The BRITI training program will offer both introductory and advanced courses on the use of medical imaging in trials, including specific evaluation methods. Customized modules for specific trials can also be developed to train pharmaceutical personnel, on-site investigators and blinded readers.
For more information, visit www.rad-md.net/info or call 267-247-5544 ext. 500.
About RadMDRadMD, Inc. provides consulting, training, and blinded reader services to the pharmaceutical and biotech industry. Services include defining and developing imaging strategies in clinical development programs, education and training through BRITI (the Blinded Reader & Investigator Training Institute), and the sourcing and management of blinded readers for clinical trials.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
March 6th 2025Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a statistically significant and high level of pain reduction compared to placebo.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Data Show Efficacy of Tezspire Treating Chronic Rhinosinusitis with Nasal Polyps
March 4th 2025Phase III WAYPOINT trial shows Tezspire (tezepelumab) significantly reduces nasal polyp size and congestion severity in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, while also decreasing the need for surgery and systemic glucocorticoids.
